Core Insights - Senti Biosciences, Inc. has completed enrollment in its Phase 1 clinical trial for SENTI-202, a first-in-class CAR NK cell therapy targeting CD33 and FLT3 in patients with relapsed or refractory acute myeloid leukemia (R/R AML) [1][2][3] - The clinical data presented at the ASH 2025 Annual Meeting showed deep, minimal residual disease (MRD)-negative, durable complete remissions and a favorable safety profile [1][2] - The company is planning to advance SENTI-202 into a pivotal study for R/R AML and is evaluating potential expansions to newly diagnosed AML and pediatric AML, with discussions with the FDA expected in the first half of 2026 [1][3] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][8] - SENTI-202 is designed to selectively target and eliminate hematologic malignancies while sparing healthy bone marrow cells, featuring an OR GATE for activation and a NOT GATE for protection of healthy cells [5] - The therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may facilitate an expedited development and review process [1][6]

DENVER, Feb. 11, 2026 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the undisputed global leader in the development and commercialization of spider silk, is entering a new phase of commercial scale-up as it accelerates production to meet growing demand from global brands. Kraig Labs utilizes advanced gene-editing techniques ...

Core Insights - Global CFO turnover is increasing, with the role becoming more complex and high-stakes in the C-suite [1][2] Group 1: CFO Appointments and Exits - Global CFO appointments reached a seven-year high in 2025 with 316 new CFOs, a 10% increase from 2024 and 12% above the long-term average of 281 [3] - The S&P 500 contributed significantly, with companies hiring a record 106 CFOs in 2025, up 19% from 89 in 2024 and well above the seven-year average of 86 [4] - CFO exits worldwide totaled 262, a 2% increase from 2024 and 5% above the seven-year average, but appointments outpaced exits by 54 roles, marking the widest gap since tracking began in 2019 [4] Group 2: Role Complexity and Expectations - The CFO role is under increasing pressure, with expanded responsibilities including enterprise-wide cost transformation and large-scale operating model redesigns [5] - Boards expect CFOs to be primary communicators with investors regarding strategy and performance, adding to the complexity of the role [5] - Technology and AI are becoming central topics in CFO searches, with companies seeking experienced leaders who can navigate major enterprise-wide changes [6] Group 3: Factors Driving Turnover - Record CEO turnover and rising shareholder activism are contributing to CFO churn, with CEO changes in 2025 being 21% above the eight-year average [7] - Activist campaigns have increased, prompting boards to reassess the suitability of their CFOs for future challenges [7] - Retirement is a significant factor, with about 62% of exiting CFOs retiring in 2025, up from 50% in 2024 [8] Group 4: Trends in CFO Pipeline - First-time CFOs make up 57% of incoming global CFOs in 2025, while experienced CFO appointments rose to 135, the highest in seven years, indicating a demand for leaders who can deliver quick impact [9] - Companies are largely unprepared for turnover, with only 16% of CFOs reporting a proactive succession plan [11] Group 5: Future Outlook - CFO turnover is expected to remain high due to ongoing complexity, elevated CEO turnover, and activist pressure, with expectations for the role continuing to grow [12]

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational medicine for the treatment of Autosomal Dominant Optic Atrophy (ADOA). ADOA is a rare genetic disease that causes progressive and irreversible vision loss in both eyes starting in the first de. ...

Core Insights - Tempest Therapeutics, Inc. is advancing its CAR-T assets post-transaction while maintaining a capital-efficient operational model [1][6] Strategic Priorities - The company will prioritize the development of its dual-targeting CD19/BCMA CAR-T program, TPST-2003, with clinical data expected from an ongoing Phase 1 trial in China and a registrational Phase 2b trial anticipated to start by the end of 2026 [2][3] - TPST-4003, an in vivo CAR-T program, aims to deliver the same dual-targeting construct without ex vivo cell manufacturing, with plans for preclinical development and potential clinical entry through a partner-funded trial [4][6] - Amezalpat is positioned for pivotal development in first-line hepatocellular carcinoma (HCC), with plans for business development discussions to advance this program [4] - The company plans to initiate a Phase 2 study of TPST-1495 in familial adenomatous polyposis (FAP), with first patient enrollment expected in Q1 2026, funded by the National Cancer Institute [5][6] Pipeline Expansion - Tempest is expanding its next-generation CAR-T pipeline, which includes additional dual-targeting CAR-T programs such as TPST-3003, TPST-2206, and TPST-3206 [6][7]

BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. The Bioxyytran Trial reports complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001). The completed Phase 2 clinical study was a randomized, double-blind, placebo-controlled, ...

BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. The Bioxyytran Trial reports complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001). The completed Phase 2 clinical study was a randomized, double-blind, placebo-controlled, ...

Core Viewpoint - The outlook on Mesoblast Limited (MESO) is bullish due to the U.S. commercial launch of Ryoncil for pediatric steroid-refractory acute graft versus host disease, indicating a transition from a development-stage biotech to a more established entity [1] Group 1: Company Analysis - Mesoblast Limited is positioned in a high-growth sector, focusing on innovative solutions that are expected to drive substantial returns [1] - The company is leveraging disruptive technologies to enhance its market presence and growth potential [1] Group 2: Market Trends - The investment strategy emphasizes a mix of fundamental analysis and future trend predictions, highlighting the importance of innovation in achieving growth [1]

Market Overview - The Australian Sharemarket saw a significant rally, with the S&P/ASX 200 closing at 9,014.80, up 147.40 points or 1.66%, marking a new 50-day high and the strongest close since late October 2025 [1][8] - The index has gained 0.97% over the last five days and is currently 1.10% off its 52-week high [2] Top Performers - AUSSIE BROADBAND LIMITED and AGL ENERGY LIMITED were the top performers, rising 14.79% and 11.75%, respectively [2][8] - Commonwealth Bank of Australia (CBA) rose 6.8% after reporting record first-half cash earnings, contributing to a 3.8% increase in heavyweight financials [3][8] Notable Stock Movements - Evolution Mining Limited (EVN) gained $1.300 to close at $16.280, an increase of 8.678% [6] - James Hardie Industries plc (JHX) advanced from $3.630 to $36.870, up 10.920% [8] - Domino's Pizza Enterprises shares rose 2.9% following the appointment of former McDonald's executive Andrew Gregory as CEO [9] Decliners - CSL Limited experienced the steepest decline, falling from $20.200 to $163.440, a drop of 11.000% [6][8] - Biotech major CSL slumped 18.2% to an eight-year low due to CEO Paul McKenzie's departure and a significant drop in half-year profit, impacting healthcare stocks which fell as much as 6.2% [8][9] - ResMed Inc. (RMD) slipped $1.760 to $36.790, down 4.566% [6]

Core Viewpoint - CSL Limited experienced a significant drop in share price, falling over 12% due to weaker half-year earnings and a sudden CEO exit, marking a shift in investor sentiment towards the company [1][5]. Financial Performance - CSL reported total revenue of US$8.3 billion for the half, a 4% decline in constant currency terms [2]. - Underlying NPATA was US$1.9 billion, reflecting a 7% decrease compared to the prior period [2]. - Reported net profit (NPAT) plummeted 81% to US$401 million, impacted by one-off restructuring costs and asset impairments totaling approximately US$1.1 billion [2]. Dividends and Cash Flow - The interim dividend remained unchanged at US$1.30 per share [3]. - Cash flow from operations increased by 3% to US$1.3 billion [3]. - Management expanded the share buyback program from US$500 million to US$750 million [3]. Business Challenges - The earnings results were negatively affected by government policy changes, restructuring costs, and impairments, particularly related to CSL Vifor and Seqirus [4]. - While some business segments are stabilizing, core areas continue to face pressure, indicating a deeper reset rather than a simple cyclical slowdown [4]. Market Reaction - The sharp market reaction was driven not only by the 7% profit decline but also by the unexpected leadership change and falling revenue, which led investors to reassess growth expectations for CSL [5]. - The market is seeking clearer evidence of operational momentum and improved margins, as well as leadership stability following recent turbulence [9]. Long-term Outlook - Despite current challenges, CSL remains a global biotechnology leader with strong intellectual property and a robust plasma infrastructure, suggesting that long-term demand drivers are still intact [7].